For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Tesamorelin
Illustration for Tesamorelin

THE PEPSRADAR ENCYCLOPEDIA

Tesamorelin

Growth hormone-releasing factor signaling

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Corrected October 11, 2026: We removed upcoming-trial records that turned out not to be real studies (fake ClinicalTrials.gov registrations). Corrections log

Tesamorelin · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (EGRIFTA SV) on DailyMed ↗

Compare: Sermorelin vs Tesamorelin · Tesamorelin vs CJC-1295

What is Tesamorelin?

Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.

Biological role or research focus

Growth hormone-releasing factor signaling.

The referenced use is HIV-associated lipodystrophy, not general weight loss.

Role reference: MedlinePlus · Tesamorelin ↗

Names you may encounter

Egrifta

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Growth-hormone-releasing factor analogue
Main research area
HIV-associated lipodystrophy
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Tesamorelin ↗

Quick answers

Is Tesamorelin FDA approved?
Yes. Egrifta (application 022505, approved November 2010. Source ↗
Is Tesamorelin safe?
Tesamorelin is a GHRH analog approved to reduce excess belly fat in people with HIV; it raises IGF-1 and can cause joint pain, swelling, injection-site reactions and higher blood sugar. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Tesamorelin banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
Has the FDA taken action over Tesamorelin?
Yes. Our records list 3 FDA actions naming it, most recently on August 24, 2026: FDA warning letter to a "research peptide" seller (Peptide Partners) naming tesamorelin, SS-31 and PT-141 as unapproved new drugs despite research-use-only labeling. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research
StudyTypePopulation / model
HIV-associated abdominal-fat trial (2007)Human randomized trial412 people with HIV and abdominal fat accumulation; 86% were men.
HIV-associated fatty-liver trial (2019)Human randomized trial61 people with HIV and a hepatic fat fraction of at least 5% were enrolled; the abstract reports 30 receiving tesamorelin and 30 placebo.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2007

HIV-associated abdominal-fat trial

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Population / model
412 people with HIV and abdominal fat accumulation; 86% were men.
Study design
Twenty-six-week placebo-controlled study.
Main finding
Visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. Some lipid measures also improved. IGF-I increased by 81.0% versus a 5.0% decrease with placebo. More tesamorelin recipients withdrew because of adverse events, despite no significant overall adverse-event difference.
Limits & context
Visceral-fat change is not the same as total body-weight loss. The trial population and HIV-associated condition are central; long-term cardiovascular benefit was not established by this endpoint.

Source: Metabolic effects of a growth hormone-releasing factor in patients with HIV. ↗

Human randomized trial · 2019

HIV-associated fatty-liver trial

Did liver fat change in people with HIV and fatty liver?

Population / model
61 people with HIV and a hepatic fat fraction of at least 5% were enrolled; the abstract reports 30 receiving tesamorelin and 30 placebo.
Study design
Double-blind multicenter placebo comparison for 12 months, followed by a six-month open-label phase. The primary endpoint was liver fat fraction measured by magnetic resonance spectroscopy.
Main finding
The between-group effect on hepatic fat fraction was −4.1 percentage points (95% CI −7.6 to −0.7), corresponding to a 37% relative reduction from baseline. Liver fat fraction fell below 5% in 35% versus 4%. Fasting glucose and HbA1c changes did not differ between groups at 12 months.
How to read it
An absolute percentage-point change in liver fat and a relative percentage reduction are different quantities. Neither describes a 37% loss of body weight.
Limits & context
The population had HIV and fatty liver; generalization beyond this group is unestablished. The primary result concerns liver fat, not proof of fewer cirrhosis complications or longer survival. The abstract calls for longer-term histology studies.

Source: Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

16 registered studies name Tesamorelin as an intervention; 2 are recruiting or under way, 0 have not started recruiting yet, 7 completed and 7 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
NCT03150511 · Johns Hopkins University
RecruitingPhase 22018-06-0136
Body Composition and Adipose Tissue in HIV
NCT03226821 · Columbia University
TerminatedPhase 42018-02-076
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
NCT06554717 · Massachusetts General Hospital
RecruitingPhase 22025-07-10100
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
NCT02572323 · University of California, San Diego
CompletedPhase 22017-02-1573
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
NCT03375788 · Massachusetts General Hospital
CompletedPhase 22019-01-1751
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
NCT00608023 · Theratechnologies
CompletedPhase 32007-08263
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
NCT01388920 · Theratechnologies
TerminatedPhase 22011-093
Tesamorelin Effects on Liver Fat and Histology in HIV
NCT02196831 · Massachusetts General Hospital
CompletedNot applicable2015-07-0161

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 16 listed studies.

Search additional PubMed records ↗

Risks & interactions

Tesamorelin is a GHRH analog approved to reduce excess belly fat in people with HIV; it raises IGF-1 and can cause joint pain, swelling, injection-site reactions and higher blood sugar.

Human safety data: FDA label

Safety is established by FDA labeling from trials in people with HIV. The long-term effects of raised IGF-1 levels are unknown. Mothers with HIV are advised not to breastfeed.

Take extra care with: Diabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeeding

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • Damage to the pituitary-hypothalamus system (pituitary removal, tumor or surgery, head radiation or head injury)
  • Active cancer
  • Allergy to tesamorelin or any ingredient
  • Pregnancy

Interactions

  • Drugs cleared by liver CYP450 enzymes, such as corticosteroids, sex hormones, seizure medicines and cyclosporine: growth hormone may change their clearance
  • Glucocorticoid replacement for adrenal insufficiency: needs may increase after starting

Serious risks

  • Possible growth or return of cancers
  • Raised IGF-1 levels with unknown long-term effects
  • Fluid retention, including carpal tunnel syndrome
  • Glucose intolerance or diabetes
  • Allergic reactions
  • Higher death risk if used during acute critical illness

Common side effects

  • joint pain
  • injection-site redness
  • injection-site itching
  • pain in arms or legs
  • swelling in legs or feet
  • muscle pain

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Egrifta SV (tesamorelin) prescribing information ↗

Key precautions

Pituitary disorders, malignancy history, pregnancy, glucose intolerance, and fluid-related symptoms require product-specific review. Endocrine monitoring matters because the intended action changes hormone signaling.

Source: MedlinePlus · Tesamorelin ↗

Trial observations are narrower than a safety guarantee

The 2007 trial found no significant between-group glycemic difference but more adverse-event withdrawals with tesamorelin. The 2019 liver-fat study reported more local injection complaints, none judged serious. These findings do not exclude uncommon or longer-term risks.

Source: Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗

Regulatory status

U.S. FDA approval
Approved
Egrifta (application 022505, approved November 2010; now Egrifta SV/WR) to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly ("tesamorelin"). source

FDA actions

  • FDA warning letter to a "research peptide" seller (Peptide Partners) naming tesamorelin, SS-31 and PT-141 as unapproved new drugs despite research-use-only labeling. (2026-08-24) source
  • FDA warning letter to a "research peptide" seller (Royal Peptides) naming tesamorelin and a tesamorelin/ipamorelin blend as unapproved new drugs. (2026-08-24) source
  • FDA warning letter to a "research peptide" seller (Peak Performance Peptides) naming tesamorelin, SS-31 and PT-141 as unapproved new drugs. (2026-08-24) source

Other notes

  • Canada, November 6, 2026: Health Canada warned consumers not to buy or inject unauthorized peptides sold online after lab tests of vials seized from a Chinese supplier found bacteria, including Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes. It seized over 11,400 vials from the supplier and two Canadian online retailers, whose websites are no longer active. Unauthorized products sold as tesamorelin were among the example products listed. Authorized drugs for sale in Canada carry an 8-digit Drug Identification Number (DIN) on the label. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

The medication reference describes adults with HIV and lipodystrophy. A change in abdominal visceral fat should not be presented as the same endpoint as scale weight or a cardiovascular-event reduction.

Source: MedlinePlus · Tesamorelin ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

It stimulates the growth-hormone-releasing-factor pathway. Clinical development measured visceral adipose tissue rather than assuming that all body fat changes equally.

Source: MedlinePlus · Tesamorelin ↗

Molecular structure

Tesamorelin: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16137828 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • The referenced use is HIV-associated lipodystrophy, not general weight loss.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Is visceral-fat reduction the same as losing that percentage of body weight?

No. Visceral fat is one measured compartment, not total body mass.

Source: MedlinePlus · Tesamorelin ↗

Does the HIV trial validate general anti-aging use?

No. It studied a defined complication in a specific population.

Source: Metabolic effects of a growth hormone-releasing factor in patients with HIV. ↗

Did the liver-fat trial prove prevention of liver failure?

No. Its primary measure was hepatic fat fraction over 12 months. Histology, clinical complications, and survival are distinct outcomes, and the population specifically had HIV.

Source: Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗

Does a 37% relative liver-fat reduction mean 37% weight loss?

No. The reported relative change concerns fat within the liver. The absolute between-group difference was 4.1 percentage points of hepatic fat fraction.

Source: Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗

How complete is this evidence review?

This profile summarizes selected NLM abstracts and linked medicine information. It is not a systematic review. Full-text verification and a comprehensive search have not been done, and this summary has not been reviewed by a medical professional.

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Tesamorelin

Download illustration ↓Source record ↗
Tesamorelin 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.